CD8A and Arthritis: A recent molecular study demonstrated that CD8+ T cells from ICI-treated patients who developed arthritis had distinct effector functions and metabolic profiles from those from ICI-treated patients who remained arthritis-free and that TNF-α inhibitors or Janus kinase (JAK) inhibitors were unable to adequately correct such dysfunction in vitro [98].